Beda Joos

List of Publications by Year
in descending order

56 papers	3,548 citations	109321 35 h-index	144013 57 g-index
59 all docs	59 docs citations	59 times ranked	4043 citing authors

#	Article	IF	Citations
1	Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine, 2005, 11, 615-622.	30.7	468
2	HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16725-16730.	7.1	273
3	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	8.9	206
4	24 Hours in the Life of HIV-1 in a T Cell Line. PLoS Pathogens, 2013, 9, e1003161.	4.7	134
5	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	5.8	127
6	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. Nucleic Acids Research, 2014, 42, e115-e115.	14.5	126
7	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. Journal of Infectious Diseases, 2003, 188, 1433-1443.	4.0	121
8	Covalent Attachment of Hybridizable Oligonucleotides to Glass Supports. Analytical Biochemistry, 1997, 247, 96-101.	2.4	116
9	Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection. Journal of Virology, 2007, 81, 11016-11031.	3.4	111
10	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. Journal of Virology, 2007, 81, 8793-8808.	3.4	85
11	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. PLoS ONE, 2010, 5, e13310.	2.5	84
12	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases, 2011, 53, 1271-1279.	5.8	84
13	HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids, 2003, 17, 195-199.	2.2	82
14	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. Antiviral Therapy, 2011, 16, 535-545.	1.0	77
15	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology, 2004, 326, 113-129.	2.4	76
16	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. Journal of Virology, 2005, 79, 8454-8469.	3.4	76
17	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids, 2004, 18, 1951-1953.	2.2	73
18	Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T Lymphocytes. Journal of Virology, 2007, 81, 9693-9706.	3.4	72

#	Article	IF	Citations
19	Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrobial Agents and Chemotherapy, 2006, 50, 1773-1779.	3.2	63
20	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. Aids, 2010, 24, 1177-1183.	2.2	62
21	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. Antiviral Therapy, 2002, 7, 91-103.	1.0	62
22	Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIVâ€1 RNA Encodingnef. Journal of Infectious Diseases, 2004, 190, 1979-1988.	4.0	56
23	Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. PLoS ONE, 2013, 8, e74249.	2.5	55
24	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection. Journal of Virology, 2003, 77, 13146-13155.	3.4	54
25	Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1135-1140.	1.1	52
26	In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers. Journal of Virology, 2008, 82, 1591-1599.	3.4	50
27	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	2.1	46
28	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	2.5	46
29	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	2.0	45
30	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology, 2008, 5, 107.	2.0	44
31	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. Journal of Virology, 2005, 79, 9026-9037.	3.4	40
32	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology, 2012, 9, 27.	2.0	39
33	Stoffwechselprodukte von Mikroorganismen. 218. Mitteilung. Versuche zur StrukturaufklÃrung von Niphimycin, 1. Teil. Reinigung und Charakterisierung der Niphimycine Î± und Î² sowie Abbau mit SalpetersÃure. Helvetica Chimica Acta, 1983, 66, 92-117.	1.6	38
34	Attenuated and Nonproductive Viral Transcription in the Lymphatic Tissue of HIVâ€1â€"Infected Patients Receiving Potent Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 189, 273-285.	4.0	37
35	Positive In Vivo Selection of the HIVâ€1 Envelope Protein gp120 Occurs at Surfaceâ€Exposed Regions. Journal of Infectious Diseases, 2007, 196, 313-320.	4.0	36
36	Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antiviral Therapy, 2002, 7, 91-103.	1.0	36

#	Article	IF	Citations
37	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	4.0	35
38	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 2010, 165, 151-160.	2.1	33
39	Equal Amounts of Intracellular and Virionâ€Enclosed Hepatitis C Virus RNA Are Associated with Peripheralâ€Blood Mononuclear Cells In Vivo. Journal of Infectious Diseases, 2006, 194, 1713-1723.	4.0	25
40	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 250-256.	2.1	23
41	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection <i>in vivo</i>. Antiviral Therapy, 2003, 8, 97-104.	1.0	23
42	Stoffwechselprodukte von Mikroorganismen. 219. Mitteilung. Versuche zur StrukturaufklÃrung von Niphimycin, 2. Teil. Die Konstitution von Desmalonyl-niphimycin I. Helvetica Chimica Acta, 1983, 66, 226-258.	1.6	21
43	The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. Journal of Antimicrobial Chemotherapy, 1995, 36, 137-155.	3.0	20
44	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. PLoS Computational Biology, 2014, 10, e1003871.	3.2	19
45	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. PLoS ONE, 2014, 9, e114111.	2.5	17
46	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	1.0	13
47	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	2.1	12
48	HIV replication elicits little cytopathic effects in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. Journal of Medical Virology, 2006, 78, 1141-1146.	5.0	12
49	Long term accuracy of fluorescence polarization immunoassays for gentamicin, tobramycin, netilmicin and vancomycin. Journal of Antimicrobial Chemotherapy, 1989, 24, 797-803.	3.0	9
50	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2011, 203, 791-797.	4.0	9
51	Stoffwechselprodukte von Mikroorganismen. 190. Mitteilung. Ãœber das 4-Oxo-homotyrosin, ein Abbauprodukt des Echinocandins B. Helvetica Chimica Acta, 1980, 63, 250-254.	1.6	6
52	Identification of fluorescent glycopeptide derivatives by two consecutive high pressure liquid chromatographic procedures.. Journal of Antibiotics, 1988, 41, 302-307.	2.0	5
53	Reply to correspondence â€˜Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a â€œstochasticâ€•processâ€™ by Gonzalez et al., Retrovirology 2017. Retrovirology, 2017, 14, 14.	2.0	3
54	Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells. Aids, 2000, 14, 752-754.	2.2	3

#	Article	IF	Citations
55	Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 2010, 10, 365-372.	2.3	2
56	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. Viruses, 2022, 14, 406.	3.3	1